Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.77 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 7/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25230453 | 0.86 | MEN1 (0.72) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL8661871 | 0.85 | MEN1 (0.82) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL6689489 | 0.85 | TSHR (0.72) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL8401925 | 0.84 | KMT2A (0.79) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL2351620 | 0.84 | MEN1 (0.79) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL15267699 | 0.82 | KMT2A (0.60) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL5803980 | 0.82 | MEN1 (0.77) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL21590314 | 0.82 | MEN1 (0.83) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL5803982 | 0.82 | MEN1 (0.77) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL5008292 | 0.82 | MEN1 (0.77) | MEN1KMT2ARAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111171035-B | Preparation method and application of 4-phenoxyphenyl pyrazolopyrimidine amide derivative | 山东大学 | 2021-03-30 | — | — | CN | disclosed |
| CN-111171035-A | Preparation method and application of 4-phenoxyphenyl pyrazolopyrimidine amide derivative | 山东大学 | 2020-05-19 | — | — | CN | disclosed |
| EP-1954287-B2 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-02-24 | — | — | EP | disclosed |
| EP-1730121-B1 | 1,4-DIARYL-DIHYDROPYRIMIDIN-2-ONES AND THEIR USE AS HUMAN NEUTROPHIL ELASTASE INHIBITORS | BAYER IP GMBH (DE) | 2013-08-07 | — | — | EP | disclosed |
| US-8343987-B2 | Heterocyclic derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-01-01 | — | — | US | disclosed |
| US-8334290-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| EP-1954287-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110262658-A1 | PROCESS AND DEVICE FOR TREATING THE COATING OF THERMOPLASTIC RESIN CONTAINERS | ZOPPAS MATTEO | 2011-10-27 | — | — | US | disclosed |
| US-7893073-B2 | Heterocyclic derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-22 | — | — | US | disclosed |
| US-20100184788-A1 | HETEROCYCLIC DERIVATIVES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-07-22 | — | — | US | disclosed |
| WO-2007070173-A2 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20050054582-A1 | Para-amino benzoic acids as integrin antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-10 | — | — | US | disclosed |
| EP-1448180-A1 | PARA-AMINO BENZOIC ACIDS AS INTEGRIN ANTAGONISTS | Bayer HealthCare AG (DE) | 2004-08-25 | — | — | EP | disclosed |
| US-20030232868-A1 | Cyclic carboxylic acids as integrin antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003030889-A1 | PARA-AMINO BENZOIC ACIDS AS INTEGRIN ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2003-04-17 | — | — | WO | disclosed |
| WO-2003030889-A1 | PARA-AMINO BENZOIC ACIDS AS INTEGRIN ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2003-04-17 | — | — | WO | disclosed |
| EP-1276714-A2 | CYCLIC CARBOXYLIC ACIDS AS INTEGRIN ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001081298-A2 | CYCLIC CARBOXYLIC ACIDS AS INTEGRIN ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2001-11-01 | — | — | WO | disclosed |
| US-5741926-A | ANTIDIABETIC AGENT | SHAMAN PHARMACEUTICALS, INC. (US) | 1998-04-21 | — | — | US | disclosed |
| WO-1997030019-A1 | ANILINE DERIVATIVES HAVING ANTIHYPERGLYCEMIC ACTIVITY | SHAMAN PHARMACEUTICALS, INC. (US) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054582-A1 | Para-amino benzoic acids as integrin antagonists | ITGB7, ICAM1, ITGB1 | MEN1 3861/4885KMT2A 4348/4885RAB9A 1498/4885 |
| US-20030232868-A1 | Cyclic carboxylic acids as integrin antagonists | ITGA1, ITGB1, ITGA2B | MEN1 4563/4885KMT2A 4302/4885RAB9A 1327/4885 |
| US-20100184788-A1 | HETEROCYCLIC DERIVATIVES | TNNI3, TNNT2, CYP11B2 | MEN1 4474/4885KMT2A 4568/4885RAB9A 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.